{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:18:32Z","timestamp":1779931112253,"version":"3.53.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AR064194"],"award-info":[{"award-number":["T32 AR064194"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Apotex, Barr Laboratories, Inc."},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kali Laboratories, Inc."},{"DOI":"10.13039\/100004319","name":"Pfizer, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hoffman La Roche-Genentech"},{"name":"Sandoz Pharmaceuticals"},{"name":"Genzyme Sanofi-Aventis"},{"name":"Takeda Pharmaceutical Company Limited"},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCB, USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our aim is to add to the limited existing prospective data on IL-1 inhibitor use in pregnancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were obtained from the Organization of Teratology Information Specialists Autoimmune Disease in Pregnancy Project, a prospective cohort study of pregnancy outcomes in the USA and Canada. Eligible women were enrolled prior to 19 weeks\u2019 gestation between 2004 and 2017. Outcomes were obtained by maternal interview and medical record abstraction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Five pregnancies with anakinra exposure were identified, all resulting in full-term singleton live births with no major or long-term complications. Three maternal subjects used anakinra for adult-onset Still\u2019s disease and two for systemic JIA. For all individuals who discontinued anakinra, some amount of steroid medication was necessary for treatment of disease flare. Two maternal subjects developed oligohydramnios, one also with pregnancy-induced hypertension. Two women had Caesarian sections, one medically indicated and one scheduled. One infant had low birth weight, but follow-up records indicated normal adjusted weight at 1 year. Three women successfully breastfed their infants, at least two of whom continued anakinra while breastfeeding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Anakinra was used successfully in five full-term pregnancies; however, two subjects developed oligohydramnios, a process that can be linked to fetal renal anomalies. Given previously reported cases of congenital renal anomalies associated with both antenatal anakinra use and maternal hyperthermia, the relationship between maternal IL-1 inhibitor use, uncontrolled maternal febrile disease and fetal outcomes should be further explored.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/key093","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T20:12:03Z","timestamp":1521663123000},"page":"1271-1275","source":"Crossref","is-referenced-by-count":34,"title":["Five successful pregnancies with antenatal anakinra exposure"],"prefix":"10.1093","volume":"57","author":[{"given":"Chelsey J F","family":"Smith","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina D","family":"Chambers","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California San Diego, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"key":"2020043006560342700_key093-B1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020043006560342700_key093-B2","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","article-title":"International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors","volume":"56","author":"Youngstein","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2020043006560342700_key093-B3","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1002\/art.38811","article-title":"Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS)","volume":"66","author":"Chang","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020043006560342700_key093-B4","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1136\/ard.2008.105833","article-title":"A patient\u2019s wish: anakinra in pregnancy","volume":"68","author":"Berger","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020043006560342700_key093-B5","first-page":"1021","article-title":"Successful outcome of two pregnancies in patients with adult onset Still\u2019s disease treated with IL-1 receptor antagonist (anakinra)","volume":"29","author":"Fischer-Betz","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2020043006560342700_key093-B6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5152\/eurjrheum.2017.16075","article-title":"Anakinra use during pregnancy: report of a case with Familial Mediterranean Fever and infertility","volume":"4","author":"\u0130lgen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"2020043006560342700_key093-B7","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1136\/annrheumdis-2015-eular.5788","article-title":"The pregnancy outcomes in patients who are exposed to IL-1 blockade with anakinra","volume":"74","author":"Ozdogan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020043006560342700_key093-B8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2174\/138920012800166607","article-title":"Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn","volume":"13","author":"Antonucci","year":"2012","journal-title":"Curr Drug Metab"},{"key":"2020043006560342700_key093-B9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/bdra.10130","article-title":"Maternal febrile illnesses, medication use, and the risk of congenital renal anomalies","volume":"67","author":"Abe","year":"2003","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"2020043006560342700_key093-B10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/REP-14-0614","article-title":"Anakinra and etanercept prevent embryo loss in pregnant nonobese diabetic mice","volume":"149","author":"Wang","year":"2015","journal-title":"Reproduction"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/7\/1271\/33147455\/key093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/7\/1271\/33147455\/key093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T11:31:29Z","timestamp":1588246289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/7\/1271\/4969305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":10,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,4,12]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key093","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7]]},"published":{"date-parts":[[2018,4,12]]}}}